Frankfurt
12.08.26 | 08:03
3,584 Euro
+1,99 % +0,070
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 3,668 | 3,794 | 20:16 | |
| 3,694 | 3,768 | 20:11 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 22.07. | Hansa Biopharma GAAP EPS of SEK -2.56, revenue of SEK 48.1M | 3 | Seeking Alpha | ||
| 22.07. | Hansa Biopharma Q2 2026 slides: €115M deal, US launch prep advance | 6 | Investing.com | ||
| 22.07. | Hansa Biopharma AB: Hansa Biopharma Reports Second Quarter and First Half Year 2026 Financial Results | 383 | GlobeNewswire (Europe) | €115 million out-licensing agreement
Positive data from European confirmatory trial (PAES)
Lund, Sweden, 22 July 2026. Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced... ► Artikel lesen | |
| 08.07. | HANSA BIOPHARMA AB: Hansa Biopharma to host Q2 2026 interim results conference call | 2 | Cision News | ||
| HANSA BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 02.07. | HANSA BIOPHARMA AB: Hansa Biopharma participating in Wedbush PacGrow Renal Summit | 1 | Cision News | ||
| 01.07. | SERB Pharmaceuticals Completes Acquisition of European and MENA Rights to Idefirix (imlifidase) from Hansa Biopharma | 293 | GlobeNewswire (Europe) | BRUSSELS, July 01, 2026 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals, a global specialty pharmaceutical company designed to address rare and urgent conditions, today announced that it has completed the... ► Artikel lesen | |
| 01.07. | Hansa Biopharma AB: Hansa Biopharma announces closing of €115 million licensing transaction with SERB Pharmaceuticals for Idefirix in Europe and MENA | 301 | GlobeNewswire (Europe) | SERB assumes responsibility for the commercialization of Idefirix in transplantation in the EU, UK, Switzerland, Norway, Liechtenstein, Iceland and MENA region
The transaction significantly strengthens... ► Artikel lesen | |
| 24.06. | HANSA BIOPHARMA AB: Hansa Biopharma announces ConfIdeS Phase 3 Abstract Selected for 'What's Hot, What's New' Plenary at ATC 2026 | 1 | Cision News | ||
| 15.06. | Hansa Biopharma AB: Hansa Biopharma appoints Adam Cutler as new Chief Financial Officer | 184 | GlobeNewswire (Europe) | Lund, Sweden, 15 June 2026. Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA) announced today the appointment of Adam Cutler as Chief Financial Officer (CFO) and a member of the Executive Committee... ► Artikel lesen | |
| 12.06. | HANSA BIOPHARMA AB: Hansa Biopharma invite to Capital Markets Day 2026 in New York | 1 | Cision News | ||
| 10.06. | Hansa Biopharma AB: Hansa Biopharma appoints Fredrik Röök as VP Business Development | 186 | GlobeNewswire (Europe) | Lund, Sweden, 10 June 2026. Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA) today announced that Fredrik Röök has been appointed as VP Business Development effective 17th August. Mr Röök will report... ► Artikel lesen | |
| 02.06. | HANSA BIOPHARMA AB: Hansa Biopharma participating in Jefferies Global Healthcare Conference in New York | 1 | Cision News | ||
| 01.06. | Hansa Biopharma AB: Bulletin from the Annual General Meeting in Hansa Biopharma AB (publ) | 203 | GlobeNewswire (Europe) | Lund, Sweden, June 1, 2026. Hansa Biopharma AB (publ), "Hansa" (Nasdaq Stockholm: HNSA), has today on June 1, 2026 held its Annual General Meeting. The Annual General Meeting was held by physical presence... ► Artikel lesen | |
| 29.05. | HANSA BIOPHARMA AB: Hansa Biopharma's CEO Renée Aguiar-Lucander named one of Sweden's Most Influential Business Women of 2026 | 1 | Cision News | ||
| 27.05. | Hansa Biopharma AB: Hansa Biopharma reports positive efficacy and safety results from Idefirix European post authorization study in kidney transplantation | 610 | PR Newswire | The 1-year graft failure-free survival was 90%, which is clinically meaningful and supports full marketing authorization submissionIdefirix was generally well tolerated with a safety profile... ► Artikel lesen | |
| 26.05. | Hansa Biopharma trial results to be presented at ATC in June | 2 | Investing.com | ||
| 26.05. | Hansa Biopharma AB: Hansa Biopharma Announces Late-Breaking Abstract from ConfIdeS Phase 3 Trial Selected for Oral Presentation at ATC 2026 | 584 | PR Newswire | LUND, Sweden, May 26, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (NASDAQ Stockholm: HNSA), today announced that results from its US Phase 3 ConfIdeS trial... ► Artikel lesen | |
| 20.05. | SERB Pharmaceuticals erwirbt von Hansa Biopharma europäische und MENA-Rechte an Idefirix (Imlifidase) für 115 Mio. € | 451 | GlobeNewswire (Deutschland) | BRÜSSEL, May 20, 2026 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals ("SERB") und Hansa Biopharma AB ("Hansa") (Nasdaq Stockholm: HNSA) gaben heute bekannt, dass sie eine Vereinbarung getroffen haben, nach... ► Artikel lesen | |
| 19.05. | Hansa Biopharma Signs IDEFIRIX Licensing Deal With SERB | 1 | Contract Pharma | ||
| 19.05. | SERB To Buy Hansa Biopharma's Idefirix Rights In Europe, MENA For EUR 115 Mln | 1 | RTTNews |
1 2 3 Weiter >>
44 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 81,00 | +1,44 % | BERENBERG stuft Biontech auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Biontech nach Zahlen zum zweiten Quartal von 140 auf 132 US-Dollar gesenkt, die Einstufung aber auf "Buy" belassen. Die Produkt-Pipeline... ► Artikel lesen | |
| EVOTEC | 3,850 | +3,89 % | EQS-News: Evotec SE: Evotec und Odyssey Therapeutics starten KI-gestützte F&E-Kooperation in Autoimmun- und Entzündungserkrankungen | EQS-News: Evotec SE
/ Schlagwort(e): Sonstiges
Evotec und Odyssey Therapeutics starten KI-gestützte F&E-Kooperation in Autoimmun- und Entzündungserkrankungen
06.08.2026... ► Artikel lesen | |
| MODERNA | 55,41 | +5,64 % | Börse am Morgen: Deutsche Telekom, Merck, Moderna, Siemens, Börsentermine - Nord/LB | Die deutsche Industrie bestätigt ihren Aufwärtstrend. Das Neugeschäft wuchs im Juni wegen vieler Großaufträge im Maschinenbau und für Elektrotechnik um 3,1% zum Vormonat, wie das Statistische Bundesamt... ► Artikel lesen | |
| VALNEVA | 2,426 | -3,92 % | Valneva vor den Halbjahreszahlen: Spannung steigt bei 2,44 Euro Marke | ||
| NOVAVAX | 6,910 | +0,44 % | Novavax, Inc.: Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights | Reported total revenue of $57 million for the second quarter of 2026 and raised full-year 2026 Revenue Framework
Improved GAAP Combined R&D and SG&A expense... ► Artikel lesen | |
| HEIDELBERG PHARMA | 2,420 | -3,97 % | Heidelberg Pharma: Was die Halbjahreszahlen über die Zukunft verraten | Bei Biotech-Unternehmen sagt eine einzelne Zahlenreihe selten alles, doch manchmal markiert sie einen Wendepunkt. Bei der Heidelberg Pharma AG (ISIN: DE000A11QVV0) könnte der Mitte Juli vorgelegte Halbjahresbericht... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 46,625 | -0,41 % | CRISPR Therapeutics AG: CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results | ZUG, Switzerland and BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the second quarter ended June 30, 2026. "The second quarter reflected... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 688,40 | -0,39 % | Megatrend Folger: Regeneron zündet den Kursturbo | Regeneron hat mit seinen jüngsten Quartalszahlen die Erwartungen deutlich übertroffen. Dupixent, Eylea in der höheren Dosierung und Libtayo wachsen kräftig, während die Aktie ihre monatelange Schwächephase... ► Artikel lesen | |
| OCUGEN | 1,210 | +2,20 % | Ocugen Provides Business Update with Second Quarter 2026 Financial Results | Conference Call and Webcast Today at 8:30 a.m. ET Received U.S. Food and Drug Administration (FDA) clearance to initiate OCU410 Phase 3 trial for geographic atrophy (GA), secondary to dry age-related... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 0,672 | +1,66 % | Inovio Pharmaceuticals Q2 2026 Earnings Preview | ||
| INFLARX | 1,790 | +3,05 % | InflaRx N.V.: InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones | Announced advancement of izicopan in ANCA-associated vasculitis (AAV) and select renal diseases; clinical preparations ongoing as plannedInitiated feasibility assessment for broadened strategy for... ► Artikel lesen | |
| SCORPIUS | - | - | Antares Global launches Scorpius MGA platform under Ian Morris | ||
| VIVORYON THERAPEUTICS | 1,130 | 0,00 % | Vivoryon Therapeutics N.V. Reports H1 2026 Financial Results and Provides Business Update | Vivoryon Therapeutics N.V. Reports H1 2026 Financial Results and Provides Business Update
Strategic partnering remains a key priority, with multiple strategic discussions progressing, including... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 61,40 | +1,89 % | BioMarin Pharmaceutical Inc.: BioMarin Reports Second Quarter 2026 Financial and Operating Results | Second Quarter 2026 Total Revenues Increased 20% Year-over-year to $990 million
Stronger Growth Expectations Drive Increased Guidance for Full-year 2026 Total Revenues... ► Artikel lesen | |
| ABIVAX | 109,50 | -0,45 % | EQS-News: ABIVAX: Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod | EQS-News: ABIVAX
/ Key word(s): Regulatory Admission
Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod
30.07.2026 / 22:05 CET/CEST
The issuer... ► Artikel lesen |
Das Unternehmen HANSA BIOPHARMA AB kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 3,584 Euro und damit +1,99 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HANSA BIOPHARMA AB finden Sie auf Wallstreet Online.